Rebecca L Robinson

Ms. Rebecca L Robinson

Value Evidence and Outcomes, Eli Lilly and Company, Indianapolis, Indiana, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2020 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
RRRebecca L Robinson
Rebecca L Robinson
DRDorene M. Rentz
Dorene M. Rentz
JAJeffrey Scott Andrews
Jeffrey Scott Andrews
AZAnthony Zagar
Anthony Zagar
YKYongin Kim
Yongin Kim
HFHoward M. Fillit
Howard M. Fillit
Background: Costs associated with early stages of Alzheimer’s disease (AD; mild cognitive impairment [MCI] and mild dementia [MILD]) are understudied. Objective: To compare costs associated with MCI and MILD due to AD in the United States. Methods: D

1 October 2012 in Pain Medicine
Verified
Journal Article
Open access
PDF file
RRRebecca L Robinson
Rebecca L Robinson
KKKurt Kroenke
Kurt Kroenke
PMPhilip Mease
Philip Mease
DWDavid A. Williams
David A. Williams
YCYi Chen
Yi Chen
BMBill McCarberg
Bill McCarberg
Objective. This study was designed to describe burden of illness and treatment patterns, and to examine the patient, physician, and care factors asso

1 January 2006 in Journal of Managed Care Pharmacy
Verified
Journal Article
Open access
RRRebecca L Robinson
Rebecca L Robinson
SLStacy R. Long
Stacy R. Long
SCStella Chang
Stella Chang
SAStephen Able
Stephen Able
OBOnur Baser
Onur Baser
RSRalph W. Swindle
Ralph W. Swindle
OBJECTIVE: To determine if the type of antidepressant drug is related to adherence to National Committee for Quality Assurance (NCQA) Antidepressant Medication Management (AMM) quality measures and to assess the 6-month health care costs among newly diagnosed depressed patients. METHODS: The MarketScan Commercial Claims and Encounter database for medical and pharmacy claims from January 2001 to September 2004 was used to assess adherence to the 3 AMM quality-of-care measures. AMM measures include (a) acute phase, the percentage of eligible members who remained on antidepressant medication continuously for 3 months after the initial diagnosis as determined by at least 84 days supply of antidepressant drugs during the first 114 days following receipt of the index antidepressant; (b) continuation phase, the percentage of eligible members who remained on antidepressant medication continuously for the 6 months after the initial diagnosis as determined by at least 180 days supply of antidepressants during the f...

1 September 2013 in Pain Medicine
Verified
Journal Article
Open access
PDF file
RRRebecca L Robinson
Rebecca L Robinson
KKKurt Kroenke
Kurt Kroenke
DWDavid A. Williams
David A. Williams
PMPhilip Mease
Philip Mease
YCYi Chen
Yi Chen
BMBill McCarberg
Bill McCarberg
Objective. To describe 12-month treatment patterns and outcomes for patients starting a new medication for fibromyalgia in routine clinical practice.De

25 October 2022 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
ACAnn Colosia
Ann Colosia
ANAnnete Njue
Annete Njue
ZBZahid Bajwa
Zahid Bajwa
EDErika Dragon
Erika Dragon
RRRebecca L Robinson
Rebecca L Robinson
SRSteven H Richiemer
Steven H Richiemer
Bone pain is one of the most common forms of pain reported by cancer patients with metastatic disease. We conducted a review of oncology literature to further understand the epidemiology of and treatment approaches for metastatic cancer–induced bone pain and the effect of treatment of painful bone metastases on the patient’s quality of life. Two-thirds of patients with advanced, metastatic, or terminal cancer worldwide experience pain. Cancer pain due to bone metastases is the most common form of pain in patients with advanced disease and has been shown to significantly reduce patients’ quality of life. Treatment options for cancer pain due to bone metastases include nonsteroidal anti-inflammatory drugs, palliative radiation, bisphosphonates, denosumab, and opioids. Therapies including palliative radiation and opioids have strong evidence supporting their efficacy treating cancer pain due to bone metastases; other therapies, like bisphosphonates and denosumab, do not. There is sufficient evidence that patients who experience pain relief after radiation therapy have improved quality of life; however, a substantial proportion are nonresponders. For those still requiring pain management, even with available analgesics, many patients are undertreated for cancer pain due to bone metastases, indicating an unmet need. The studies in this review were not designed to determine why cancer pain due to bone metastases was undertreated. Studies specifically addressing cancer pain due to bone metastases, rather than general cancer pain, are limited. Additional research is needed to determine patient preferences and physician attitudes regarding choice of analgesic for moderate to severe cancer pain due to bone metastases.

1 June 2003
Verified
Journal Article
Closed access
RRRebecca L Robinson
Rebecca L Robinson
HBHoward G Birnbaum
Howard G Birnbaum
MMMelissa A Morley
Melissa A Morley
TSTamar Sisitsky
Tamar Sisitsky
PGPaul E Greenberg
Paul E Greenberg
ACAmi J Claxton
Ami J Claxton